Transgene : TG4010 fails – time to build a new equity story – Neutral vs Buy
>TG4010 fails in phase II in non-small cell lung cancer - TNG yesterday evening announced the eagerly-awaited result for the phase II trial of TG4010, its therapeutic vaccine developed in non-small cell lung cancer (NSCLC; with low expression of PDL1 (< 50%)). Unfortunately, it is negative, i.e. the efficacy of the drug falls short of the company’s expectations (data not revealed). To recap, TG4010 is the most advanced therapeutic vaccine in terms of develop...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.